Effects of Moringa Oleifera on hsCRP and Hgba1c Level of Patients in Ospital ng Maynila Medical Center Diabetic Clinic
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02308683|
Recruitment Status : Completed
First Posted : December 4, 2014
Last Update Posted : December 4, 2014
Current evidence supports a central role of inflammation in the pathogenesis of atherosclerosis and diabetes [57-60]. Diabetes Mellitus type 2 is an inflammatory atherothrombotic condition associated with high prevalence of thrombotic cardiovascular disease. In patient with DM type 2, this inflammation is reflected by elevated plasma levels of several biomarkers of inflammation such as C-reactive protein (CRP) [51-55]. HsCRP is considered as a strong predictive of cardiovascular risks and death [53, 61-72]. Besides its predictive role in determining cardiovascular risk, there is some evidence that CRP may represent an active participant in atherogenesis . CRP is expressed in human atherosclerotic plaques and both vascular cells and monocytes/macrophages appear to represent a significant source of CRP in the inflammatory vessel wall .
Among the DM risk factors (like hypertension, atherogenic dyslipidemia, insulin resistance, impaired fibrinolysis, inflammatory profile), definitely, inflammation is the neglected one.
Moringa oleifera has been suggested to exert anti-inflammatory effects  and hypoglycemic property . As with many reports of the nutritional or medicinal value of a natural product, there are an alarming number of purveyors of "healthful" food who are now promoting M. oleifera as a panacea. While much of this recent enthusiasm indeed appears to be justified, it is critical to separate scientific evidence from anecdote.
Herein, the investigators will investigate the effects of Moringa oleifera leaves supplementation on levels of inflammatory marker specifically hsCRP, hgbA1c level and clinical outocome in diabetic patients through a cohort study.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes||Dietary Supplement: Moringa oleifera||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||The Effects of Moringa Oleifera Supplements on hsCRP and HgbA1c Levels of Patients in Ospital ng Maynila Medical Center Diabetic Clinic: A Prospective Cohort Study|
|Study Start Date :||August 2014|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||November 2014|
Experimental: hsCRP, Hgba1c
Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
Dietary Supplement: Moringa oleifera
12 weeks supplementation
Other Name: Malungay
- Post treatment mean HsCRP [ Time Frame: 12 weeks ]
- Post treatment mean hgba1c [ Time Frame: 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02308683
|Principal Investigator:||Rainier Mozo, Dr||Ospital ng Maynila Medical Center Department of Internal Medicine and ICU|